Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

Neuro-Oncology

Volumn 16, Issue 4, 2014, Pages 589-593

  Liao, Bing ^a,b   Shroff, Sheetal ^a,b   Kamiya Matsuoka, Carlos ^a,b   Tummala, Sudhakar ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Immune related adverse events; Ipilimumab; Metastatic melanoma; Transverse myelitis

Indexed keywords

ARGININE DEIMINASE; CARBOPLATIN; CHOLINERGIC RECEPTOR ANTIBODY; CISPLATIN; CREATINE KINASE; DACARBAZINE; DOXORUBICIN; IMMUNOGLOBULIN; IPILIMUMAB; METHYLPREDNISOLONE; PACLITAXEL; PYRIDOSTIGMINE; STEROID; VEMURAFENIB; VINBLASTINE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; CHEMOEMBOLIZATION; CHOROID MELANOMA; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COLITIS; DERMATITIS; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; ELECTRODIAGNOSIS; ENUCLEATION; FATIGUE; FECES INCONTINENCE; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LOW DRUG DOSE; LUMBAR PUNCTURE; MALE; METASTATIC MELANOMA; MIDDLE AGED; MOTOR NERVE CONDUCTION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; MYASTHENIA GRAVIS; MYELITIS; MYOSITIS; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; NEUROLOGICAL COMPLICATION; ODYNOPHAGIA; OUTCOME ASSESSMENT; PARESTHESIA; PLASMAPHERESIS; SKIN TINGLING; STEROID THERAPY; TREATMENT RESPONSE; URINE RETENTION; UROGENITAL TRACT DISEASE; UVEA MELANOMA; UVEITIS; WALKING DIFFICULTY; WEAKNESS;

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; IMMUNE-RELATED ADVERSE EVENTS; IPILIMUMAB; METASTATIC MELANOMA; TRANSVERSE MYELITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NERVOUS SYSTEM DISEASES; PROGNOSIS;

EID: 84896934432     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou001     Document Type: Article

References (12)

1. Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci. 2009;36(4): 518-520.
2. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockage therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013;2013:857519.
3. Patel SP,Woodman SE. Profile of ipilimumab and its role in treatment of metastatic melanoma. Drug Des Devel Ther. 2011;5:489-495.
4. Andrews S, Holden R. Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res. 2012;4:299-307.
5. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697.
6. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol. 2011;22(4):991-993.
7. Koski CL, Baumgarten M, Magder LS, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2009;277(1-2):1-8.
8. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17(3):356-363.
9. Anthoney DA, Bone I, Evans TR. Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma. Ann Oncol. 2000;11(9):1197-1200.
10. Awad A, Stüve O. Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol. 2011;9(3):417-428.
11. Hoejberg L, Bastholt L, Schmidt H. Interleukin-6 and melanoma. Melanoma Res. 2012;22(5):327-333.
12. Yervoy (ipilimumab) injection, prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2011. Available at: http://packageinserts.bms.com. Accessed January 18, 2012.